A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
| dc.contributor.author | İstemi SERİN | |
| dc.contributor.author | Mehmet DOĞU | |
| dc.contributor.author | Omer EKINCI | |
| dc.contributor.author | Gülsüm AKGÜN ÇAĞLIYAN | |
| dc.contributor.author | Abdülkadir BAŞTÜRK | |
| dc.contributor.author | Merih Reis ARAS | |
| dc.contributor.author | Sinan DEMİRCİOĞLU | |
| dc.contributor.author | Burhan TURGUT | |
| dc.contributor.author | Mustafa MERTER | |
| dc.contributor.author | Sibel HACIOĞLU | |
| dc.contributor.author | Metin BAGCİ | |
| dc.contributor.author | Murat ALBAYRAK | |
| dc.contributor.author | Serdal KORKMAZ | |
| dc.contributor.author | Mehmet Ali ERKURT | |
| dc.contributor.author | Mehmet Sinan DAL | |
| dc.contributor.author | Fadime DURSUN | |
| dc.contributor.author | Anıl TOMBAK | |
| dc.contributor.author | İsmet AYDOĞDU | |
| dc.contributor.author | Turgay ULAS | |
| dc.contributor.author | Fevzi ALTUNTAŞ | |
| dc.date.accessioned | 2024-07-24T09:14:25Z | |
| dc.date.available | 2024-07-24T09:14:25Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Introduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: ≥35%) by imaging and control of hematocrit levels (≤45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman’s rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman’s rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher’s exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups. | |
| dc.identifier.DOI-ID | 10.4274/imj.galenos.2023.66742 | |
| dc.identifier.issn | 2619-9793 | |
| dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/26067 | |
| dc.language.iso | eng | |
| dc.title | A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera | |
| dc.type | Araştırma Makalesi |